Q2 2026 Absci Corp Earnings Call Transcript
Key Points
- Absci Corp (ABSI) reported positive interim Phase I data for ABS-201, showing favorable safety and tolerability, with a half-life supporting dosing only 2-3 times over six months.
- The company secured a $40 million strategic investment from Eli Lilly, which also includes collaboration on clinical development and participation on the Endometriosis Advisory Board.
- Absci Corp (ABSI) completed a $100 million financing round, extending its cash runway into the second half of 2028 to support key catalysts.
- The ATLAS platform has identified new potential indications for the prolactin receptor franchise, including pattern hair loss and endometriosis, enhancing pipeline optionality.
- Modeling suggests ABS-201 can achieve >90% receptor occupancy with 2-3 doses, potentially driving superior efficacy compared to competitors like HMI-115.
- Absci Corp (ABSI) has not yet reported proof-of-concept data for ABS-201, with interim data expected only in late 2026 and full data in early 2027.
- The company faces significant competition in the hair loss market, with existing treatments like minoxidil and finasteride, and recent data from Veradermics highlights the high bar for efficacy.
- The change in indication naming from androgenetic alopecia to pattern hair loss may create confusion or require additional regulatory clarity.
- The company's strategy to commercialize ABS-201 itself may require substantial capital and resources, posing execution risks.
- The endometriosis Phase II trial is only planned to initiate in Q4 2026, with proof-of-concept data not expected until the second half of 2027, indicating a long timeline.
Thank you. Good day and thank you for standing by. Welcome to the Absci second quarter business update. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Alex Khan, Corporate Vice President and Investor Relations. Please go ahead.
Thank you. Earlier today, Absci released financial and operating results for the quarter ended June 30, 2026. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an email to [email protected]. An archived webcast of this call will be available for replay on Absci's Investor Relations website at investors.absci.com for at least 90 days after this call. Joining me today are Sean McClain, Absci Absci's Founder and CEO; Zach Jonasson, Chief Financial Officer and Chief Business Officer; and Ransi Somaratne, Chief Medical Officer, Head of R&D.
Before we begin, I'd
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
